Brokerages Set Natera, Inc. (NASDAQ:NTRA) PT at $120.07

Shares of Natera, Inc. (NASDAQ:NTRA) have been given an average recommendation of “Buy” by the sixteen research firms that are currently covering the company, MarketBeat reports. Sixteen analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $124.44.

NTRA has been the topic of several recent analyst reports. The Goldman Sachs Group lifted their target price on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Piper Sandler restated an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. TD Cowen raised their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. Canaccord Genuity Group increased their price objective on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Finally, Morgan Stanley boosted their target price on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th.

Natera Stock Down 1.6 %

NTRA stock opened at $120.50 on Tuesday. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The firm’s 50-day simple moving average is $123.41 and its 200 day simple moving average is $110.81. The stock has a market cap of $14.80 billion, a PE ratio of -38.62 and a beta of 1.53. Natera has a fifty-two week low of $36.90 and a fifty-two week high of $133.54.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s quarterly revenue was up 58.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.97) EPS. As a group, sell-side analysts predict that Natera will post -1.96 EPS for the current year.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 690 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $105.29, for a total transaction of $72,650.10. Following the completion of the sale, the chief financial officer now owns 75,810 shares in the company, valued at $7,982,034.90. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO Michael Burkes Brophy sold 690 shares of Natera stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $105.29, for a total value of $72,650.10. Following the completion of the transaction, the chief financial officer now owns 75,810 shares in the company, valued at approximately $7,982,034.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Daniel Rabinowitz sold 1,057 shares of the firm’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $102.77, for a total value of $108,627.89. Following the sale, the insider now directly owns 206,400 shares of the company’s stock, valued at $21,211,728. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,079 shares of company stock worth $5,627,963. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently added to or reduced their stakes in the stock. Quent Capital LLC increased its holdings in shares of Natera by 3.2% in the first quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock valued at $293,000 after purchasing an additional 99 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the period. Moss Adams Wealth Advisors LLC raised its position in shares of Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after acquiring an additional 135 shares during the last quarter. Quarry LP raised its position in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Natera during the second quarter valued at $28,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.